Idoroenyi Amanam, MD
Hematology · Duarte, CANPI 1205257920
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $36,531 of the $44,065 with a category attached, or 82.9%. 18 manufacturers reported payments, led by Incyte Corporation at 32.4% of the total. 2025 is the largest year on record at $22,670, more than ten times the $262 reported in 2019.
Across 73 payments — averaging $603.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$14K
- E.r. Squibb & Sons, L.L.C.$11K
- GSK$9K
- Rigel Pharmaceuticals, Inc.$3K
- Geron Corporation$3K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- plus $2K from 12 others
Across 801 payments — averaging $128.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sumitomo Pharma America, Inc.$101K
- Ionis Pharmaceuticals, Inc.$2K
- Incyte Corporation$60
- AbbVie$21
What the payments were for
- Consulting fees$36,53183%
- Speaking & faculty fees$2,3405%
- Travel & lodging$2,8747%
- Food & beverage$2,2435%
- Education$770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 18 | $14,280 |
| E.r. Squibb & Sons, L.L.C. | 8 | $10,821 |
| GSK | 8 | $8,943 |
| Rigel Pharmaceuticals, Inc. | 5 | $3,420 |
| Geron Corporation | 5 | $2,575 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,100 |
| Bristol Myers Squibb | 4 | $825 |
| Novartis | 9 | $283 |
| Johnson & Johnson | 3 | $194 |
| Jazz Pharmaceuticals Inc. | 2 | $163 |
| Pfizer | 2 | $133 |
| Gilead | 1 | $125 |
| AbbVie | 2 | $52 |
| Sumitomo Pharma America, Inc. | 1 | $49 |
| Sobi, Inc | 1 | $33 |
| Amgen | 1 | $33 |
| Genentech USA, Inc. | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$44,065 in reported general payments places this provider in the 70th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Duarte
- Amrita KrishnanDuarte$671K
- Vinod PullarkatDuarte$576K
- Alexey DanilovDuarte$407K
- Tycel PhillipsDuarte$348K
- Haris AliDuarte$310K
- Amandeep SalhotraDuarte$214K
- Tanya SiddiqiDuarte$199K
- Scott GoldsmithDuarte$180K
- Ibrahim AldossDuarte$175K
- Alex HerreraDuarte$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.